Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cerebrolysin in Acute Ischemic Stroke Patients Undergoing EVT
NCT06070753Unknown
- Sponsor
- Shaare Zedek Medical Center
- Start
- Oct 2023
- Primary completion
- Jun 2024
- Modality
- Native Peptides
- Countries
- 1
01
Overview
Open-label, single-arm trial of cerebrolysin in ischemic stroke, sponsored by Shaare Zedek Medical Center. Primary endpoint: Modified Rankin Scale at 90 days. Status: unknown.
02
Drugs
cerebrolysin
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT06070753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06070753.